Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed BRILINTA (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared…

ABC Partner and Corporate Member Esperion announced this week that their NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine is now available in U.S. pharmacies. ABC…

ANN ARBOR, Mich., March 30, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announced today that NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine is now available…

New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s FARXIGA (dapagliflozin) reduced the incidence of the…

Coronavirus: A Message From ABC President Michelle A. Albert, MD, MPH Dear Friends and Colleagues, At this time in our global history, we are severely challenged by the ongoing COVID-19/coronavirus…

– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients – – NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism – – Fills an Unmet…